1. Home
  2. CTRM vs LGVN Comparison

CTRM vs LGVN Comparison

Compare CTRM & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$2.13

Market Cap

21.2M

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.79

Market Cap

24.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRM
LGVN
Founded
2016
2014
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.2M
24.7M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
CTRM
LGVN
Price
$2.13
$0.79
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
74.8K
266.4K
Earning Date
04-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
N/A
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$0.48
52 Week High
$2.65
$1.80

Technical Indicators

Market Signals
Indicator
CTRM
LGVN
Relative Strength Index (RSI) 53.38 49.35
Support Level $1.95 $0.73
Resistance Level $2.18 $0.85
Average True Range (ATR) 0.15 0.05
MACD 0.01 0.01
Stochastic Oscillator 47.04 63.64

Price Performance

Historical Comparison
CTRM
LGVN

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: